论文部分内容阅读
目的观察扶正解毒方联合阿德福韦酯治疗HBeAg阴性慢性乙型肝炎的临床疗效。方法将68例HBeAg阴性慢性乙型肝炎患者随机分成治疗组34例,和对照组34例,均口服阿德福韦酯10mg/d,连服52周,治疗组同时联合应用扶正解毒方治疗26周,观察治疗52周时肝功能指标ALT、AST、TBIL变化及治疗26周,52周时HBV-DNA转阴率(HBV-DNA<500 copies/ml为阴性)。结果 2组肝功能指标ALT、AST、TBIL、水平在治疗52周时与治疗前比较,差异均有统计学意义(P<0.05)且治疗组各项指标在治疗52周与治疗前差值与对照组比较,差异有统计学意义(P<0.05)。治疗26周时,2组血清HBV-DNA转阴率,分别为79.4%与64.7%差异有统计学意义(P<0.05),治疗52周时,2组血清HBV-DNA转阴率,分别为82.3%与76.5%差异无统计学意义(P>0.05)。结论扶正解毒方联合阿德福韦酯治疗HBeAg阴性慢性乙型肝炎,在抗病毒改善肝功能方面均具有协同作用。
Objective To observe the clinical efficacy of Fuzheng Jiedu Decoction combined with adefovir dipivoxil in the treatment of HBeAg-negative chronic hepatitis B. Methods Sixty-eight patients with HBeAg-negative chronic hepatitis B were randomly divided into treatment group (n = 34) and control group (n = 34). All patients were given oral adefovir dipivoxil 10mg / d for 52 weeks. The treatment group was treated with Fuzheng Jiedu Decoction 26 The changes of ALT, AST, TBIL and the negative rate of HBV-DNA (HBV-DNA <500 copies / ml) were observed at week 52 and week 52 after 52 weeks of treatment. Results The levels of ALT, AST and TBIL in group 2 were significantly different from those before treatment at 52 weeks of treatment (P <0.05), and the difference between the two groups was statistically significant The difference between the control group, the difference was statistically significant (P <0.05). After 26 weeks of treatment, the rates of HBV-DNA negative conversion in the two groups were 79.4% and 64.7%, respectively (P <0.05). At 52 weeks of treatment, the serum HBV-DNA negative rates in the two groups were There was no significant difference between 82.3% and 76.5% (P> 0.05). Conclusion Fuzheng Jiedu Decoction combined with adefovir dipivoxil in the treatment of HBeAg-negative chronic hepatitis B has a synergistic effect in the aspects of antivirus and improving liver function.